Reckitt Benckiser Group (RKT) Consumer Analyst Group of New York Conference (CAGNY) 2026 summary

Strategic transformation and portfolio focus

• Sharpened portfolio by divesting non-core segments, including Essential Home, and focusing on 11 Powerbrands that contribute 80% of core net revenue in FY24, with strong global equity.

• Mead Johnson remains under review for future options, further simplifying the business.

• Streamlined management structure and new global operating model increase accountability, standardization, and executional excellence.

• Core business generates about GBP 10 billion in net sales, with emerging markets comprising 40% of revenue.

• Capital allocation prioritizes organic growth, progressive dividends, and returning surplus cash to shareholders.

Growth drivers and market opportunities

• Four core categories—self care, germ protection, household care, and intimate wellness—benefit from strong tailwinds and underpenetration.

• Emerging markets now surpass North America and Europe in $25K+ households, reaching 316m in 2024, offering major growth potential.

• Premiumisation and category expansion are key levers in developed markets, while penetration and education drive emerging market growth.

• High growth runways identified in self care (66% more health-conscious), germ protection (58% growth in disease-causing germs), and household care (14% global dishwasher penetration).

• Intimate wellness remains underpenetrated, with only 1% of sex occasions including branded products.

Brand building, innovation, and AI integration

• Iconic brands like Dettol, Lysol, Finish, Durex, and Mucinex lead their categories globally, supported by innovation and consumer trust.

• Dettol is used over a billion times a year and is the #1 trusted brand in multiple countries.

• AI-driven tools accelerate concept generation, innovation, and consumer insight, reducing time-to-market and improving success rates.

• Durex drives market leadership and premiumisation through material science innovation, including non-latex and hyaluronic acid condoms.

• Mucinex continues to launch first-in-category cold and flu remedies, including the first 12-hour multi-symptom product in the US.